FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946660125> ?p ?o ?g. }

• W2946660125 endingPage "2921" @default.
• W2946660125 startingPage "2917" @default.
• W2946660125 abstract "In mantle cell lymphoma (MCL), cyclin D1 combines with CDK4/6 to phosphorylate Rb, releasing a break on the G1 to S phase cell cycle. Palbociclib is a specific, potent, oral inhibitor of CDK4/6 capable of inducing a complete, prolonged G1 cell cycle arrest (pG1) in Rb+ MCL cells. The proteasome inhibitor bortezomib is approved by the US Food and Drug Administration for treatment of mantle cell lymphoma. Palbociclib-induced pG1 appears to sensitize MCL cells to killing by low-dose bortezomib, potentially improving its activity and tolerability. We conducted a phase 1 trial of palbociclib plus bortezomib in patients with previously treated MCL (NCT01111188). Patients received palbociclib at 75 mg (dose level 1), 100 mg (dose level 2), or 125 mg (dose levels 3 and 4) on days 1-12 of each 21-day cycle in addition to intravenous bortezomib 1.0 mg/m2 (dose levels 1, 2, 3) or 1.3 mg/m2 (dose level 4) on days 8, 11, 15 and 18. A total of 19 patients with a median age of 64 and an average of 2 prior therapies were enrolled. Two subjects experienced dose limiting toxicity (DLT): thrombocytopenia (dose level 1) and neutropenia (dose level 3). Although no DLTs were seen at dose level 4, all patients required dose delays during cycle 2 due to cytopenias, and the study team decided to stop the trial. Four of 19 patients achieved a clinical response, including one patient with a complete response. Three patients received treatment for more than one year, including one patient receiving single-agent palbociclib for more than 6 years. The combination of palbociclib 125 mg on days 1-12 plus bortezomib 1.0 mg/m2 on days 8, 11, 15, and 18 of a 21-day cycle is feasible and active in previously treated MCL, with the primary toxicity being myelosuppression. The regimen may be worthy of further evaluation in patients with non-blastoid MCL following failure of other newer agents." @default.
• W2946660125 created "2019-05-29" @default.
• W2946660125 creator A5000554189 @default.
• W2946660125 creator A5010045617 @default.
• W2946660125 creator A5013974745 @default.
• W2946660125 creator A5026842309 @default.
• W2946660125 creator A5037882455 @default.
• W2946660125 creator A5040141808 @default.
• W2946660125 creator A5047613865 @default.
• W2946660125 creator A5054231625 @default.
• W2946660125 creator A5080145536 @default.
• W2946660125 creator A5090324252 @default.
• W2946660125 date "2019-05-23" @default.
• W2946660125 modified "2023-10-07" @default.
• W2946660125 title "A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma" @default.
• W2946660125 cites W2041694372 @default.
• W2946660125 cites W2044348066 @default.
• W2946660125 cites W2125211913 @default.
• W2946660125 cites W2147422161 @default.
• W2946660125 cites W2158945674 @default.
• W2946660125 cites W2767838333 @default.
• W2946660125 cites W2914575774 @default.
• W2946660125 doi "https://doi.org/10.1080/10428194.2019.1612062" @default.
• W2946660125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31120355" @default.
• W2946660125 hasPublicationYear "2019" @default.
• W2946660125 type Work @default.
• W2946660125 sameAs 2946660125 @default.
• W2946660125 citedByCount "19" @default.
• W2946660125 countsByYear W29466601252020 @default.
• W2946660125 countsByYear W29466601252021 @default.
• W2946660125 countsByYear W29466601252022 @default.
• W2946660125 countsByYear W29466601252023 @default.
• W2946660125 crossrefType "journal-article" @default.
• W2946660125 hasAuthorship W2946660125A5000554189 @default.
• W2946660125 hasAuthorship W2946660125A5010045617 @default.
• W2946660125 hasAuthorship W2946660125A5013974745 @default.
• W2946660125 hasAuthorship W2946660125A5026842309 @default.
• W2946660125 hasAuthorship W2946660125A5037882455 @default.
• W2946660125 hasAuthorship W2946660125A5040141808 @default.
• W2946660125 hasAuthorship W2946660125A5047613865 @default.
• W2946660125 hasAuthorship W2946660125A5054231625 @default.
• W2946660125 hasAuthorship W2946660125A5080145536 @default.
• W2946660125 hasAuthorship W2946660125A5090324252 @default.
• W2946660125 hasConcept C121608353 @default.
• W2946660125 hasConcept C126322002 @default.
• W2946660125 hasConcept C143998085 @default.
• W2946660125 hasConcept C197934379 @default.
• W2946660125 hasConcept C2775930923 @default.
• W2946660125 hasConcept C2776364478 @default.
• W2946660125 hasConcept C2776694085 @default.
• W2946660125 hasConcept C2777063308 @default.
• W2946660125 hasConcept C2777478702 @default.
• W2946660125 hasConcept C2777525834 @default.
• W2946660125 hasConcept C2778375690 @default.
• W2946660125 hasConcept C2779338263 @default.
• W2946660125 hasConcept C2779744173 @default.
• W2946660125 hasConcept C2779788671 @default.
• W2946660125 hasConcept C29730261 @default.
• W2946660125 hasConcept C530470458 @default.
• W2946660125 hasConcept C71924100 @default.
• W2946660125 hasConcept C90924648 @default.
• W2946660125 hasConcept C98274493 @default.
• W2946660125 hasConceptScore W2946660125C121608353 @default.
• W2946660125 hasConceptScore W2946660125C126322002 @default.
• W2946660125 hasConceptScore W2946660125C143998085 @default.
• W2946660125 hasConceptScore W2946660125C197934379 @default.
• W2946660125 hasConceptScore W2946660125C2775930923 @default.
• W2946660125 hasConceptScore W2946660125C2776364478 @default.
• W2946660125 hasConceptScore W2946660125C2776694085 @default.
• W2946660125 hasConceptScore W2946660125C2777063308 @default.
• W2946660125 hasConceptScore W2946660125C2777478702 @default.
• W2946660125 hasConceptScore W2946660125C2777525834 @default.
• W2946660125 hasConceptScore W2946660125C2778375690 @default.
• W2946660125 hasConceptScore W2946660125C2779338263 @default.
• W2946660125 hasConceptScore W2946660125C2779744173 @default.
• W2946660125 hasConceptScore W2946660125C2779788671 @default.
• W2946660125 hasConceptScore W2946660125C29730261 @default.
• W2946660125 hasConceptScore W2946660125C530470458 @default.
• W2946660125 hasConceptScore W2946660125C71924100 @default.
• W2946660125 hasConceptScore W2946660125C90924648 @default.
• W2946660125 hasConceptScore W2946660125C98274493 @default.
• W2946660125 hasFunder F4320306378 @default.
• W2946660125 hasFunder F4320306536 @default.
• W2946660125 hasFunder F4320308295 @default.
• W2946660125 hasFunder F4320308982 @default.
• W2946660125 hasIssue "12" @default.
• W2946660125 hasLocation W29466601251 @default.
• W2946660125 hasLocation W29466601252 @default.
• W2946660125 hasOpenAccess W2946660125 @default.
• W2946660125 hasPrimaryLocation W29466601251 @default.
• W2946660125 hasRelatedWork W1728255343 @default.
• W2946660125 hasRelatedWork W1912976527 @default.
• W2946660125 hasRelatedWork W2086024298 @default.
• W2946660125 hasRelatedWork W2095669071 @default.
• W2946660125 hasRelatedWork W2254776899 @default.
• W2946660125 hasRelatedWork W2914575774 @default.
• W2946660125 hasRelatedWork W2946660125 @default.
• W2946660125 hasRelatedWork W3016781567 @default.

• next